Neratinib
This targeted cancer therapy is taken as a tablet to treat HER2-positive early-stage breast cancer, typically used after completing treatment with another HER2-targeted medicine. It works by blocking the HER2 protein that drives the growth of certain breast cancer cells.
Moleküler Ağırlık
557,0000 g/mol
LogP
4,90
TPSA
112,00 Ų
Lipinski RO5
Geçer
Terapötik Alanlar
Etki Mekanizması
Targets the HER2 (ErbB2) receptor tyrosine kinase, blocking HER2-mediated signaling that drives proliferation in HER2-overexpressing cancer cells.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Targets the HER2 (ErbB2) receptor tyrosine kinase, blocking HER2-mediated signaling that drives proliferation in HER2-overexpressing cancer cells.
2D Yapı
Cite this structure
Embed this structure
SMILES
CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C
InChI
InChI=1S/C30H29ClN6O3/c1-4-39-28-16-25-23(15-26(28)36-29(38)9-7-13-37(2)3)30(20(17-32)18-34-25)35-21-10-11-27(24(31)14-21)40-19-22-8-5-6-12-33-22/h5-12,14-16,18H,4,13,19H2,1-3H3,(H,34,35)(H,36,38)/b9-7+
Molecular Formula
C30H29ClN6O3
HBD / HBA
2 / 8
Döndürülebilir Bağlar
11
Ağır Atomlar
40
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
This targeted cancer therapy is taken as a tablet to treat HER2-positive early-stage breast cancer, typically used after completing treatment with another HER2-targeted medicine. It works by blocking the HER2 protein that drives the growth of certain breast cancer cells.
Targets the HER2 (ErbB2) receptor tyrosine kinase, blocking HER2-mediated signaling that drives proliferation in HER2-overexpressing cancer cells.
Yes, Neratinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL180022. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 9915743. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="neratinib"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/neratinib/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/neratinib/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/neratinib/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="neratinib"></drugfyi-drug>